AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Declaration of Voting Results & Voting Rights Announcements Jun 5, 2012

2894_rns_2012-06-05_1385b0bc-8f3f-4668-8550-ff0b5e9d5d87.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Biotage AB changes in number of shares and votes

As previously announced, the shareholders resolved at theAnnual General Meeting held on 26April 2012 to withdraw 6,381,983 shares, which had been repurchased under the company's re-purchase program. Following withdrawal of these shares the number of outstanding shares and votes amounts to 73,255,705 as of 31 May 2012.

Contact:

Torben Jörgensen, President and CEO Tel: +46 707 49 05 84, [email protected]

Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The informationwas submitted for publication at 9.00 on 5 June 2012.

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include theworld's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered inUppsala and has offices in theUS, UK, China and Japan. Biotage has 270 employees and had sales of 428.4 MSEKin 2011. Biotage is listed on theNASDAQOMXNordic Stockholmstock exchange. Website: www.biotage.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.